Lancashire Teaching Hospitals NHS Foundation Trust

Preston, Lancashire PR2 9HT

1 studies enrolling now · 5 studies all time

What they study most

BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Neoplasms, Carcinoma, Renal Cell, Cutaneous Melanoma, Stage II, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma

Studies at this site

• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma — Recruiting now
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers — Completed
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) — Completed
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) — Stopped early